Legal News

In a House Committee on Oversight and Accountability hearing, Democrats and Republicans took a bipartisan stance to question the role major PBMs play regarding rising drug costs in the US.

Steve Postal, JD, Director of Policy and Regulatory Affairs at the National Community Pharmacists Association (NCPA), sat down with Drug Topics to discuss Pharmacy Benefit Managers.

Steve Postal, JD, Director of Policy and Regulatory Affairs at the National Community Pharmacists Association (NCPA), discussed pharmacy benefit managers and vehicles necessary to induce reform.

House Bill (HB) 1993 seeks to increase PBM transparency and accountability in an effort to combat the rising cost of prescription drugs.

The FTC released its interim report detailing PBM practices, staggering market consolidation statistics, and the disparities between PBMs and their smaller competitors.

“Retail pharmacy is central to our future and to our overall customer and patient experience. It enables many other things, but it has to change,” said Walgreens CEO Tim Wentworth.

On the second anniversary of the overturning of Roe v Wade, check out recent coverage on abortion and contraceptive access.

Chris DesRochers, a pharmacy technician who works at a CVS in Wakefield, Rhode Island and is active in the recent organizing, discusses what motivated him and his coworkers to unionize.

Emergency department visits tripled by December 2022 compared with the pre-legalization period from January 2015 to September 2018.

In its ongoing campaign against “scope creep,” the American Medical Association argued that pharmacists don’t receive enough training. Physicians and pharmacists alike disagree.

The class action lawsuit against CVS Health, Caremark, and Aetna was announced earlier today.

Todd Eury of the Pharmacy Podcast Network is joined by Josh Bolin of the NABP to talk about DSCSA, what benefits it will provide, and how to make sure your pharmacy is ready when it goes into effect this November.

The act is currently set to go into effect in just over three months.

According to a spokesperson, the company is prepared to take the lawsuit to the Supreme Court.

The combination of Lynparza and abiraterone reduced the risk of disease progression or death by 76% vs. abiraterone alone in patients with BRCA-mutated metastatic castration-resistant prostate cancer.

Iowa's Department of Health and Human Services, which manages the two health insurers that delivered care to adults and children in the state’s Medicaid program last year, was alleged to provide inadequate mental and behavioral health care to children on Medicaid.

The antibiotic, marketed as Xacduro, is indicated for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii.

The newly FDA-approved prescription product delivers nalmefene to the nasal cavity to reverse the effects of opioid overdose.

Health plans must continue providing free screenings pending court’s further consideration of case.

The atrial fibrillation drug, asundexian, may provide protection from thrombotic events without a corresponding increase in bleeding risk.

The company that developed the treatment said it will benefit "millions" of patients.

The brand-new treatment from Elanco is currently the only approved therapeutic solution proven to treat canine parvovirus.

Despite having a highly differentiated clinical value proposition compared to branded, twice-nightly oxybates, Avadel is pricing Lumryz at $64.67 per gram or around $177,034 annually, which is on par with twice-nightly oxybate products that require chronic, middle-of-the-night awakening.

Both Democrats and Republicans voted to bring back the act that attempts to improve use of antibiotics

The NexGard COMBO topical solution from Boehringer Ingelheim helps protect cats from tapeworms and other intestinal parasites like fleas, ticks, and heartworms.

STAQ, a 503B outsourcing facility, started making desmopressin nasal spray after Ferring Pharmaceuticals suspended production nearly three years ago.

The FDA is hoping these warnings are a positive step in what will be an extremely long process of ending opioid related deaths.

The Senate Finance Committee recently released a framework for legislation, and the leaders of the “big three” PBMs are scheduled to be witnesses at another committee's hearing regarding insulin prices on May 10.